InvestorsHub Logo
Followers 827
Posts 119499
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 660

Friday, 12/03/2021 6:47:54 PM

Friday, December 03, 2021 6:47:54 PM

Post# of 750
JAK inhibitors—including ABBV’s Rinvoq and PFE’s Xeljanz—have new FDA labels that relegate these agents to the second-line setting in RA (and other inflammatory diseases) following unsuccessful treatment with a TNFa agent (such as Humira); today’s label changes are in addition to the safety warnings added to the JAK labels three months ago (#msg-165728499).

ABBV’s PR:
https://finance.yahoo.com/news/abbvie-provides-rinvoq-upadacitinib-treatment-211500945.html

Please see #msg-165728499 for related info.

Note: BMY’s TYK2 inhibitor, Deucravacitinib is not affected by the above changes because the FDA considers TYK2 a different drug class from JAK.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABBV News